Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
crossref(2024)
摘要
Supplementary Figure S2. Percent reduction in B cell numbers and B cell/T cell ratios in human CD20 transgenic mice treated with obinutuzumab or rituximab in A, Spleen and B, Lymph nodes. C, Reduction in splenic marginal zone B cells in human CD20 transgenic mice treated with obinutuzumab or rituximab (n = 2 per group).
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要